AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
AVITA Medical (NASDAQ: RCEL) announced that CEO Cary Vance will present at the 44th Annual J.P.
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) announced that CEO Cary Vance will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. PT.
A live audio webcast will be available via the company's Investor Relations Events & Presentations page and a replay will be posted after the presentation.
Details
News Market Reaction – RCEL
On Dec 19, the first trading day after this news, RCEL closed 2.98% above the previous close.
Data tracked by StockTitan Argus for the Dec 19 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 14, 2026
- Scheduled conference presentation
- Presentation time
- 5:15 p.m. Pacific Time
- J.P. Morgan conference session
Historical Context
-
Piper Sandler healthcare conference presentation and webcast access.
-
Investor webinar briefing following Q3 2025 earnings webcast.
-
Q3 2025 results with revenue decline and lowered full-year guidance.
-
Data reinforcing RECELL as standard of care in acute wound treatment.
-
Scheduling and access details for Q3 2025 earnings call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com/events-and-presentations. A replay of the webcast will be available following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.